- Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee ...

Dyno Therapeutics launches two new AAV capsids and AI platform for rare disease therapeutic development at ASGCT 2026 ...

Dyno Therapeutics launches two new AAV Capsids, AI platform for rare disease therapeutic development: Watertown, Massachusetts Saturday, May 16, 2026, 13:00 Hrs [IST] Dyno Therape ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations ...

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...

The genetic material of viruses is shielded by a protective protein covering called a capsid. Researchers in Spain have uncovered the strict selection rules that define capsid structure in spherical ...

The basic components of a virus are genetic material and a protein shell, called a capsid, that surrounds and protects the fragile nucleic acids. During the life cycle of a virus, the genetic material ...

Biogen and Capsigen have entered into a strategic research collaboration to engineer novel AAV capsids to deliver gene therapies that address the underlying genetic causes of various central nervous ...

The alternative text for this image may have been generated using AI. Figure 2: Co-localization of HP68 with HIV-1 Gag in mammalian cells. The alternative text for this image may have been generated ...